FDA approves Bylvay for treating progressive familial intrahepatic cholestasis

FDA approves Bylvay for treating progressive familial intrahepatic cholestasis

Albiero Pharma Inc. announced it received FDA approval for Bylvay to treat pruritus in all subtypes of progressive familial intrahepatic cholestasis.According to a press release, it is the first drug approved for PFIC.Bylvay (odevixibat) is a non-systemic ileal bile acid transport inhibitor. Odevixibat will not require refrigeration and is administered as a once-daily capsule or can be opened and sprinkled onto soft foods.The company will launch the treatment immediately.“Bylvay is the first ever approval by the FDA of a drug developed for a pediatric cholestatic liver disease andRead More

Share on facebook
Share on twitter
Share on linkedin